A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
Takeda · Short Bowel Syndrome
Phase 3
Recruiting
13
2026-06
Evidence dashboardStudies since 2003Updated Jul 31, 2026
TeduglutideClinical Trials.
A source-linked view of every Teduglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 50
- Recruiting
- 4
- Completed
- 39
- Terminated
- 0
- Results posted
- 20
- Average enrollment
- 40
- Countries
- 18
- Highest phase
- Phase 4
Largest indexed study
1,806 participants · NCT01990040 →Developer / research origin
Takeda
Evidence summary
Activity is not efficacy.
Teduglutide appears in 50 indexed studies: 4 recruiting, 39 completed and 20 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Teduglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)
International Centre for Diarrhoeal Disease Research, Bangladesh · Environmental Enteric Dysfunction
Phase 2
Not yet recruiting
55
2026-04
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Takeda · Short Bowel Syndrome
Not applicable
Active, not recruiting
250
2026-04
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
12
2026-03
TED_ORG: Study on Short Bowel Syndrome
Meyer Children's Hospital IRCCS · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
50
2026-02
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
600
2026-01
Showing 6 of 7 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
Assistance Publique - Hôpitaux de Paris · Short Bowel Syndrome
Phase 4
Completed
25
2025-09
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Completed
52
2025-04
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
Shire · Short Bowel Syndrome
Phase 3
Completed
61
2025-03
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
Shire · Short Bowel Syndrome
Phase 3
Completed
29
2025-03
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
Takeda · Short Bowel Syndrome
Phase 3
Completed
3
2024-05
Pediatric Teduglutide Registry
Boston Children's Hospital · Short Bowel Syndrome
Not applicable
Completed
142
2023-12
Showing 6 of 39 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Ileostomy - Stoma
Phase 3
Withdrawn
0
2023-02
Full study index
Search Teduglutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
50 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 41324792 ↗Wada M, Nakamura S, Hayashi A, Otake R, Miyamoto M, Tanaka T. Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance. Adv Ther. 2026 Jan;43(1):425-441. doi: 10.1007/s12325-025-03398-y. Epub 2025 Dec 1.Linked from NCT05023382PMID 37270289 ↗Lambe C, Talbotec C, Kapel N, Barbot-Trystram L, Brabant S, Nader EA, Pigneur B, Payen E, Goulet O. Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome. Am J Clin Nutr. 2023 Jun;117(6):1152-1163. doi: 10.1016/j.ajcnut.2023.02.019. Epub 2023 May 3.Linked from NCT03562130PMID 41858082 ↗Wendel D, Wales PW, Kocoshis S, Venick R, Carter B, Cohran V, Matthews C, Raphael BP, Robinson I, Hill S. Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide. J Pediatr Gastroenterol Nutr. 2026 Jul;83(1):54-62. doi: 10.1002/jpn3.70358. Epub 2026 Mar 19.Linked from NCT02954458PMID 38873891 ↗Wales PW, Hill S, Robinson I, Raphael BP, Matthews C, Cohran V, Carter B, Venick R, Kocoshis S. Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure. J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):290-300. doi: 10.1002/jpn3.12276. Epub 2024 Jun 14.Linked from NCT02954458PMID 41454663 ↗Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S, Miyamoto M, Nakano H, Kondo T, Ieiri S. Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study. Pediatr Int. 2026 Jan-Dec;68(1):e70301. doi: 10.1111/ped.70301.Linked from NCT05027308PMID 24486858 ↗Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. JPEN J Parenter Enteral Nutr. 2014 May;38(1 Suppl):8S-13S. doi: 10.1177/0148607114520994. Epub 2014 Jan 31.Linked from NCT04344717PMID 30136101 ↗Santamaria MM, Villafranca JJA, Abiles J, Lopez AF, Rodas LV, Goitia BT, Navarro PU. Systematic review of drug bioavailability following gastrointestinal surgery. Eur J Clin Pharmacol. 2018 Dec;74(12):1531-1545. doi: 10.1007/s00228-018-2539-9. Epub 2018 Aug 22.Linked from NCT04344717PMID 28355459 ↗Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017 May 1;2(5):566-574. doi: 10.1001/jamacardio.2017.0364.Linked from NCT04344717
Related pages
Keep researching Teduglutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.